Pfizer beats Q2 2025 estimates, raises EPS guidance, boasts a 7%+ dividend yield, yet faces patent and pricing risks. See why ...

BioNTech SE BNTX -0.15% Get Free Report reported a narrower loss for the second quarter on Monday. The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Pfizer (NYSE:PFE) shares traded higher in the premarket on Tuesday after the New York-based pharma giant reported better-than ...

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

Live Updates Live Coverage Has Ended Monday Wrap-up 4:26 pm The Vanguard S&P 500 ETF closed at 580.14 Monday, up 1.5% — almost an exact mirror of Friday’s 1.6% decline. ViaSat Goes to the Moon 1:21 pm ...

BioNTech (BNTX) recently reported significant improvements in its financial performance, with quarterly sales nearly doubling compared to the previous year and a substantial reduction in net losses.

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...